Phase II trial of zolpidem in patients with progressive supranuclear palsy
Phase of Trial: Phase II/III
Latest Information Update: 19 Aug 2015
At a glance
- Drugs Zolpidem (Primary)
- Indications Progressive supranuclear palsy
- Focus Therapeutic Use
- Sponsors Sellas Life Sciences Group
- 19 Aug 2015 Sellas expects to initiate this study in the first half of 2016 with completion anticipated by second half of 2017.
- 03 Dec 2014 New trial record
- 14 Oct 2014 SELLAS has signed an agreement with Pharmaceutical Product Development (PPD) to advance the clinical development of its drug and this trial is expected to be initiated in the fourth quarter of 2014, according to a media release.